Literature DB >> 30963445

Cost-effectiveness analysis of low versus high dose colistin in the treatment of multi-drug resistant pneumonia: a comment.

Effat Davoudi-Monfared1, Maryam Taghizadeh-Ghehi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30963445     DOI： 10.1007/s11096-019-00822-6

Source DB:  PubMed          Journal:  Int J Clin Pharm


× No keyword cloud information.
  4 in total

1.  Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment?

Authors:  Gamze Kalin; Emine Alp; Ramazan Coskun; Hayati Demiraslan; Kürsat Gündogan; Mehmet Doganay
Journal:  J Infect Chemother       Date:  2012-05-29       Impact factor: 2.211

Review 2.  Clinical and microbiological end points in the treatment of pneumonia.

Authors:  Daniel M Musher
Journal:  Clin Infect Dis       Date:  2008-12-01       Impact factor: 9.079

3.  Cost-effectiveness analysis of low versus high dose colistin in the treatment of multi-drug resistant pneumonia in Saudi Arabia.

Authors:  Abdul Karim Suleman Cara; Syed Tabish Razi Zaidi; Fatima Suleman
Journal:  Int J Clin Pharm       Date:  2018-08-16

4.  Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria.

Authors:  S T R Zaidi; S Al Omran; A S M Al Aithan; M Al Sultan
Journal:  J Clin Pharm Ther       Date:  2014-03-05       Impact factor: 2.512
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.